BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 30179054)

  • 1. An introduction to the clinical practice of theranostics in oncology.
    Turner JH
    Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in theranostics and challenges for the future.
    Turner JH
    Br J Radiol; 2018 Nov; 91(1091):20170893. PubMed ID: 29565650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
    Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
    Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic approaches in nuclear medicine: current status and future prospects.
    Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
    Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
    Choudhury P; Gupta M
    Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oncological theranostics in nuclear medicine].
    Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
    Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.
    Turner JH
    Cancer Biother Radiopharm; 2019 Apr; 34(3):135-140. PubMed ID: 30973278
    [No Abstract]   [Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
    Schaefer N; Prior J
    Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
    Burkett BJ; Bartlett DJ; McGarrah PW; Lewis AR; Johnson DR; Berberoğlu K; Pandey MK; Packard AT; Halfdanarson TR; Hruska CB; Johnson GB; Kendi AT
    Radiol Imaging Cancer; 2023 Jul; 5(4):e220157. PubMed ID: 37477566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
    Høilund-Carlsen PF
    Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
    Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
    Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostic applications of antibodies in oncology.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; van Herpen CM; Oyen WJ; van der Graaf WT; Boerman OC
    Mol Oncol; 2014 Jun; 8(4):799-812. PubMed ID: 24725480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
    Duan H; Iagaru A; Aparici CM
    Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostics in Brain Tumors.
    Shooli H; Nemati R; Ahmadzadehfar H; Aboian M; Jafari E; Jokar N; Nabipour I; Dadgar H; Gholamrezanezhad A; Larvie M; Assadi M
    PET Clin; 2021 Jul; 16(3):397-418. PubMed ID: 34053584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should we introduce clinical PET in the UK? The oncologists need to have a view.
    Price P; Laking G
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):172-5. PubMed ID: 15191003
    [No Abstract]   [Full Text] [Related]  

  • 19. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted radionuclide therapy: frontiers in theranostics.
    Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.